Pancreatic Cancer: Pathogenesis and Clinical Studies DOI Creative Commons
Kexun Zhou,

Yingping Liu,

Chuanyun Tang

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(4)

Published: April 1, 2025

ABSTRACT Pancreatic cancer (PC) is a highly lethal malignancy, with pancreatic ductal adenocarcinoma (PDAC) being the most common and aggressive subtype, characterized by late diagnosis, progression, resistance to conventional therapies. Despite advances in understanding its pathogenesis, including identification of genetic mutations (e.g., KRAS, TP53, CDKN2A, SMAD4) dysregulated signaling pathways KRAS–MAPK, PI3K–AKT, TGF‐β pathways), effective therapeutic strategies remain limited. Current treatment modalities chemotherapy, targeted therapy, immunotherapy, radiotherapy, emerging therapies such as antibody–drug conjugates (ADCs), chimeric antigen receptor T (CAR‐T) cells, oncolytic viruses (OVs), vaccines, bispecific antibodies (BsAbs), face significant challenges. This review comprehensively summarizes these approaches, emphasizing their mechanisms, limitations, potential solutions, overcome bottlenecks. By integrating recent advancements outlining critical challenges, this aims provide insights into future directions guide development more for PC, specific focus on PDAC. Our work underscores urgency addressing unmet needs PDAC therapy highlights promising areas innovation field.

Language: Английский

Pancreatic Cancer: Pathogenesis and Clinical Studies DOI Creative Commons
Kexun Zhou,

Yingping Liu,

Chuanyun Tang

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(4)

Published: April 1, 2025

ABSTRACT Pancreatic cancer (PC) is a highly lethal malignancy, with pancreatic ductal adenocarcinoma (PDAC) being the most common and aggressive subtype, characterized by late diagnosis, progression, resistance to conventional therapies. Despite advances in understanding its pathogenesis, including identification of genetic mutations (e.g., KRAS, TP53, CDKN2A, SMAD4) dysregulated signaling pathways KRAS–MAPK, PI3K–AKT, TGF‐β pathways), effective therapeutic strategies remain limited. Current treatment modalities chemotherapy, targeted therapy, immunotherapy, radiotherapy, emerging therapies such as antibody–drug conjugates (ADCs), chimeric antigen receptor T (CAR‐T) cells, oncolytic viruses (OVs), vaccines, bispecific antibodies (BsAbs), face significant challenges. This review comprehensively summarizes these approaches, emphasizing their mechanisms, limitations, potential solutions, overcome bottlenecks. By integrating recent advancements outlining critical challenges, this aims provide insights into future directions guide development more for PC, specific focus on PDAC. Our work underscores urgency addressing unmet needs PDAC therapy highlights promising areas innovation field.

Language: Английский

Citations

0